- Home
- VIVS vs NCNA Comparison
VIVS vs NCNA Comparison
Compare VIVS & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- NCNA
- Stock Information
- Founded
- VIVS 2007
- NCNA 1997
- Country
- VIVS United States
- NCNA United Kingdom
- Employees
- VIVS N/A
- NCNA N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- NCNA Health Care
- Exchange
- VIVS Nasdaq
- NCNA Nasdaq
- Market Cap
- VIVS 8.1M
- NCNA 7.6M
- IPO Year
- VIVS N/A
- NCNA 2017
- Fundamental
- Price
- VIVS $2.28
- NCNA $3.66
- Analyst Decision
- VIVS
- NCNA
- Analyst Count
- VIVS 0
- NCNA 0
- Target Price
- VIVS N/A
- NCNA N/A
- AVG Volume (30 Days)
- VIVS 1.4M
- NCNA 285.2K
- Earning Date
- VIVS 11-12-2025
- NCNA 11-24-2025
- Dividend Yield
- VIVS N/A
- NCNA N/A
- EPS Growth
- VIVS N/A
- NCNA N/A
- EPS
- VIVS N/A
- NCNA N/A
- Revenue
- VIVS $142,000.00
- NCNA N/A
- Revenue This Year
- VIVS $42.38
- NCNA N/A
- Revenue Next Year
- VIVS $15.42
- NCNA N/A
- P/E Ratio
- VIVS N/A
- NCNA N/A
- Revenue Growth
- VIVS 94.52
- NCNA N/A
- 52 Week Low
- VIVS $1.41
- NCNA $2.78
- 52 Week High
- VIVS $21.96
- NCNA $332.00
- Technical
- Relative Strength Index (RSI)
- VIVS 43.02
- NCNA 41.09
- Support Level
- VIVS $2.05
- NCNA $3.61
- Resistance Level
- VIVS $3.20
- NCNA $4.07
- Average True Range (ATR)
- VIVS 0.31
- NCNA 0.33
- MACD
- VIVS -0.02
- NCNA -0.13
- Stochastic Oscillator
- VIVS 20.00
- NCNA 4.33
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.